NEXTIMMUNE
NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy and good safety without adverse effects as known from conventional immunosuppressants.
NEXTIMMUNE
Industry:
Biotechnology
Founded:
2021-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.nextimmune.com
Status:
Active
Total Funding:
150 K CHF
Investors List
Venture Kick
Venture Kick investment in Grant - NextImmune
Official Site Inspections
http://www.nextimmune.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 76.223.54.146
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "NextImmune"
Home - Neximmune
NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology that uses natural biology to orchestrate a targeted cell …See details»
Our Company - Neximmune
Our company was founded in 2011, with the exclusive licensing of our core technology from the Johns Hopkins University. NexImmune is a clinical-stage biotechnology company developing …See details»
Leadership - Neximmune
NexImmune - Crunchbase Company Profile & Funding
NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology. View contacts for NexImmune to access new leads and connect with decision-makers.See details»
NextImmune - Crunchbase Company Profile & Funding
NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with …See details»
NexImmune Announces Formation of Autoimmune and Infectious …
GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to …See details»
NexImmune Announces Preliminary Phase 1/2 NEXI …
GAITHERSBURG, Md., Dec. 12, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune …See details»
NexImmune Reports Fourth Quarter and Full Year 2022 Financial …
Mar 28, 2023 · NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, …See details»
NexImmune Announces Closing of $3.67 Million ... - Markets Insider
Feb 6, 2024 · NexImmune is developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The …See details»
Our Technology - Neximmune
NexImmune’s precision technology and unique scientific approach offer promise in restoring hope for patients suffering from cancer and immune-mediated diseases by directing specific immune responses to target and attack those …See details»
NexImmune Announces Closing of $3.67 Million Registered Direct …
GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted …See details»
NextImmune wins CHF 150,000 to develop a new generation of ...
Jun 27, 2022 · NextImmune will use the CHF 150,000 Venture Kick financing to reach the next value inflection point, enabling further preclinical development. A properly functioning immune …See details»
NexImmune Announces IND Clearance by the US FDA for
GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy …See details»
NexImmune Announces Data Showing AIM ACT T cells Enhance …
Feb 16, 2023 · NexImmune is a clinical stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, …See details»
NexImmune Presents Initial Positive Data from the NEXI-001 Phase …
GAITHERSBURG, Md., June 05, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to …See details»
Biozentrum start-up NextImmune supported by Venture Kick
Jun 29, 2022 · NextImmune, a spin-off from the Biozentrum of the University of Basel, has received financial support of 150,000 Swiss francs from the Venture Kick funding initiative. The …See details»
NexImmune Announces Publication in Frontiers in Medicine …
Jan 18, 2023 · NexImmune is focused on an injectable, off-the-shelf nanoparticle that can activate, tolerize or destroy CD8+ T cells in vivo and continues to move this product toward the …See details»
Nextmune: Global #1 in allergy and dermatolgy for companion …
Access your patients personalized interactive food list. We continuously organize seminars, webinars and other educational activities for veterinary practitioners. Register for upcoming …See details»
Our Pipeline - Neximmune
NexImmune is acting with urgency to meet the needs of waiting patients by advancing our clinical pipeline of immunotherapies for cancer. We are also continuing our preclinical research on …See details»
Newsroom - Neximmune
Oct 24, 2023 · Exciting things are happening at NexImmune. Below you will find the latest news about our company, technology, pipeline and leadership.See details»